Literature DB >> 19828873

Progression-free survival remains debatable endpoint in cancer trials.

Rabiya Tuma.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19828873     DOI： 10.1093/jnci/djp399

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  9 in total

1.  Weighed, measured, and still searching: bevacizumab in the treatment of unselected patients with advanced breast cancer.

Authors:  Gilberto Lopes; Rebecca Dent
Journal:  Oncologist       Date:  2011-12-08

2.  Joint modeling of multiple longitudinal patient-reported outcomes and survival.

Authors:  Laura A Hatfield; Mark E Boye; Bradley P Carlin
Journal:  J Biopharm Stat       Date:  2011-09       Impact factor: 1.051

Review 3.  Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?

Authors:  Lothar R Pilz; Christian Manegold; Gerald Schmid-Bindert
Journal:  Transl Lung Cancer Res       Date:  2012-03

4.  Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer.

Authors:  Yingwei Qi; Katie L Allen Ziegler; Shauna L Hillman; Mary W Redman; Steven E Schild; David R Gandara; Alex A Adjei; Sumithra J Mandrekar
Journal:  Cancer       Date:  2012-03-20       Impact factor: 6.860

5.  CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen.

Authors:  Jean E Abraham; Mel J Maranian; Kristy E Driver; Radka Platte; Bolot Kalmyrzaev; Caroline Baynes; Craig Luccarini; Mitul Shah; Susan Ingle; David Greenberg; Helena M Earl; Alison M Dunning; Paul D P Pharoah; Carlos Caldas
Journal:  Breast Cancer Res       Date:  2010-08-23       Impact factor: 6.466

6.  Time-dependent endpoints as predictors of overall survival in multiple myeloma.

Authors:  Jorge Félix; Filipa Aragão; João M Almeida; Frederico J Calado; Diana Ferreira; António B S Parreira; Ricardo Rodrigues; João F R Rijo
Journal:  BMC Cancer       Date:  2013-03-16       Impact factor: 4.430

7.  Multiple treatment comparison meta-analyses: a step forward into complexity.

Authors:  Edward J Mills; Nick Bansback; Isabella Ghement; Kristian Thorlund; Steven Kelly; Milo A Puhan; James Wright
Journal:  Clin Epidemiol       Date:  2011-05-27       Impact factor: 4.790

8.  Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways.

Authors:  Michael Ermisch; Anna Bucsics; Patricia Vella Bonanno; Francis Arickx; Alexander Bybau; Tomasz Bochenek; Marc van de Casteele; Eduardo Diogene; Jurij Fürst; Kristina Garuolienė; Martin van der Graaff; Jolanta Gulbinovič; Alan Haycox; Jan Jones; Roberta Joppi; Ott Laius; Irene Langner; Antony P Martin; Vanda Markovic-Pekovic; Laura McCullagh; Einar Magnusson; Ellen Nilsen; Gisbert Selke; Catherine Sermet; Steven Simoens; Robert Sauermann; Ad Schuurman; Ricardo Ramos; Vera Vlahovic-Palcevski; Corinne Zara; Brian Godman
Journal:  Front Pharmacol       Date:  2016-09-28       Impact factor: 5.810

Review 9.  Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion.

Authors:  Daniele Santini; Alfredo Berruti; Massimo Di Maio; Giuseppe Procopio; Sergio Bracarda; Toni Ibrahim; Francesco Bertoldo
Journal:  ESMO Open       Date:  2020-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.